CAJ | 학술논문

年龄相关性黄斑变性(age-related macular degeneration,AMD)是老年人主要致盲眼病之一.以脉络膜新生血管形成(choroidal neovascularization,CNV)为特征的湿性AMD是视力损害的首要原因.抗血管内皮生长因子(vascular endothelial growth factor-A,VEGF)制剂是治疗湿性AMD的一线药物.Aflibercept(商品名Eylea)是用于眼科治疗的抗VEGF新药,其结合范围广(可与VEGF-A,VEGF-B及胎盘生长因子结合),亲和力强,半衰期长,可延长给药间隔而达到较稳定的治疗效果.目前,有较多Aflibercept临床研究已经完成或正在进行.随着对其有效性和安全性的进一步研究,Aflibercept可为临床治疗湿性AMD提供新的选择,或可联合其他抗VEGF药物巩固和提高疗效.
년령상관성황반변성(age-related macular degeneration,AMD)시노년인주요치맹안병지일.이맥락막신생혈관형성(choroidal neovascularization,CNV)위특정적습성AMD시시력손해적수요원인.항혈관내피생장인자(vascular endothelial growth factor-A,VEGF)제제시치료습성AMD적일선약물.Aflibercept(상품명Eylea)시용우안과치료적항VEGF신약,기결합범위엄(가여VEGF-A,VEGF-B급태반생장인자결합),친화력강,반쇠기장,가연장급약간격이체도교은정적치료효과.목전,유교다Aflibercept림상연구이경완성혹정재진행.수착대기유효성화안전성적진일보연구,Aflibercept가위림상치료습성AMD제공신적선택,혹가연합기타항VEGF약물공고화제고료효.
Age-related macular degeneration(AMD) is a major cause of blindness in elderly populations.Wet AMD,which is characterized by choroidal neovascularization (CNV),is the leading cause of vision loss.Anti-VEGF therapy is the current first-line treatment for wet AMD.Aflibercept (Eylea) is the latest member in the anti-VEGF drugs for ophthalmic application.The dose interval of Aflibercept can be extended but yield stable therapeutic effect due to its wider binding range (VEGF-A,VEGF-B,placental growth factor),better affinity,as well as longer half-life.At present,quite a few clinical trials about Aflibercept application have completed or are undergoing.As further confirmation of its efficacy and safety goes on,Aflibercept,alone or in combination with other anti-VEGF agents,could become a new therapeutic option for wet AMD.